535.1

+0.17%↑

CABK

10.92

-4.42%↓

INGA

25.085

-4.05%↓

NDA.FI

16.52

-1.9%↓

BKT

14.375

-3.13%↓

535.1

+0.17%↑

CABK

10.92

-4.42%↓

INGA

25.085

-4.05%↓

NDA.FI

16.52

-1.9%↓

BKT

14.375

-3.13%↓

535.1

+0.17%↑

CABK

10.92

-4.42%↓

INGA

25.085

-4.05%↓

NDA.FI

16.52

-1.9%↓

BKT

14.375

-3.13%↓

535.1

+0.17%↑

CABK

10.92

-4.42%↓

INGA

25.085

-4.05%↓

NDA.FI

16.52

-1.9%↓

BKT

14.375

-3.13%↓

535.1

+0.17%↑

CABK

10.92

-4.42%↓

INGA

25.085

-4.05%↓

NDA.FI

16.52

-1.9%↓

BKT

14.375

-3.13%↓

Home・Akciju saraksts・Gimv NV

Gimv NV

Slēgts

SektorsFinanšu

43.9 -2.01

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

43.75

Max

44.8

Galvenie mērījumi
By Trading Economics
Ienākumi	127M
Pārdošana	-49M 65M
P/E Sektora vidējais	7.709 27.185
EPS	3.4
Dividenžu ienesīgums	5.71
Peļņas marža	195.239
Darbinieki	94
EBITDA	52M 128M

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	5.71% 4.21%

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	53M 1.7B
Iepriekšējā atvēršanas cena	45.91
Iepriekšējā slēgšanas cena	43.9

Ziņu noskaņojums

By Acuity

50%

171 / 445 Rangs Finance

Gimv NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. febr. 00:00 UTC

Karstas akcijas

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

2026. g. 4. febr. 22:55 UTC

Peļņas

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

2026. g. 4. febr. 21:44 UTC

Peļņas

Arm Holdings 3Q Profit Falls Despite Revenue Growth

2026. g. 4. febr. 21:39 UTC

Peļņas

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

2026. g. 5. febr. 00:00 UTC

Peļņas

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026. g. 5. febr. 00:00 UTC

Peļņas

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

2026. g. 4. febr. 23:46 UTC

Tirgus saruna

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026. g. 4. febr. 23:45 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

2026. g. 4. febr. 23:32 UTC

Tirgus saruna

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

2026. g. 4. febr. 22:59 UTC

Iegādes, apvienošanās, pārņemšana

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

2026. g. 4. febr. 22:30 UTC

Peļņas

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

2026. g. 4. febr. 22:30 UTC

Peļņas

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

2026. g. 4. febr. 22:21 UTC

Peļņas

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026. g. 4. febr. 22:17 UTC

Tirgus saruna

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

2026. g. 4. febr. 22:15 UTC

Tirgus saruna

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

2026. g. 4. febr. 22:00 UTC

Tirgus saruna

ESG Roundup: Market Talk

2026. g. 4. febr. 21:53 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

2026. g. 4. febr. 21:51 UTC

Peļņas

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 4. febr. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 4. febr. 21:45 UTC

Peļņas

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

2026. g. 4. febr. 21:44 UTC

Peļņas

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

2026. g. 4. febr. 21:43 UTC

Peļņas

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

2026. g. 4. febr. 21:41 UTC

Peļņas

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026. g. 4. febr. 21:36 UTC

Tirgus saruna

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

2026. g. 4. febr. 21:30 UTC

Peļņas

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026. g. 4. febr. 21:30 UTC

Peļņas

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026. g. 4. febr. 21:30 UTC

Peļņas

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Salīdzinājums

Cenas izmaiņa

Gimv NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Gimv NV — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

171 / 445 Rangs Finanšu

Finanšu rādītāji

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Gimv NV

Gimv NV is a private equity and venture capital firm specializing in direct and fund of funds investments. For direct investments, the firm specializes in buyouts, growth capital, middle market, debt, shareholder loans, seed, startups, early to mid-stage, late venture, public to private transactions, small and medium sized enterprises, later stage, mature, replacement capital, bridge financing, and recapitalization. Within fund of funds, it seeks to invest in venture capital and private equity funds. It seeks to invest in high performance growth companies that respond to that can speed up their internal growth through acquisitions. The firm typically invests in consumer, connected consumer, fintech; health and care; smart industries; and sustainable cities. Within consumer, it seeks to provide growth capital to emerging leaders. Within health and care platform, the firm seeks to invest in companies that can grow either organically or through a buy and build strategy. Within consumer, it focuses on consumer goods, food and beverage, healthy food, sport, convenience food, personal luxury, career, home & deco, baby & kids, pet products, retail, consumer services, media and content, travel and leisure, education, digital economy and online sectors. Within health and care sector, it focuses on life sciences, medtech, and health and care services. The firm focuses on biotech/biopharma comprising drugs, platform technologies, vaccines and diagnostic tests, preclinical, early clinical, and late clinical, medtech such as medical devices, consumables, IT and small equipment, and health and care services-based companies. It also seeks to be an active shareholder, preferably lead or co-lead in its investments. Within smart industries, it focuses on equipment, services and tools for resource efficient development and production, automotive and aerospace, both optimizing of the existing and development of new means of transport, software and services harnessing the flexibility of the cloud, smart data management and advanced c